De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM, Tian H, Watts JM. Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm. British Journal of Haematology. 2025;206(4):10.1111/bjh.19944
Pullarkat V, Pratz KW, Döhner H, Recher C, Thirman MJ, DiNardo CD, Fenaux P, Schuh AC, Wei AH, Pigneux A, Jang J-H, Juliusson G, Miyazaki Y, Selleslag D, Arellano ML, Liu C, Ridgeway JA, Potluri J, Schuler J, Konopleva M. Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood Cancer Journal. 2025;15(1):10.1038/s41408-025-01263-3
Borate U, Pugh K, Waller A, Welkie RL, Huang Y, Bewersdorf JP, Stahl M, DeZern AE, Platzbecker U, Sekeres MA, Wei AH, Buckstein RJ, Roboz GJ, Savona MR, Loghavi S, Hasserjian RP, Fenaux P, Sallman DA, Hourigan CS, Della Porta MG, Nimer S, Little RF, Santini V, Efficace F, Taylor J, Garcia-Manero G, Odenike O, Kim TK, Halene S, Komrokji RS, Griffiths EA, Greenberg PL, Xu ML, Xie Z, Bejar R, Sanz GF, Patnaik MM, Figueroa M, Carraway HE, Abdel-Wahab O, Starczynowski D, Padron E, Boultwood J, Gore S, Daver NG, Churpek JE, Majeti R, Bennett JM, List AF, Brunner AM, Zeidan AM. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood. 2025;145(13):10.1182/blood.2023023717
Iland HJ, Reynolds J, Boddy AV, Schultz HB, Khoo L, Fleming S, Lane SW, Weber N, Gasiorowski R, Armytage T, Harrup R, Watson A-M, Tan P, Filshie R, Kwok F, Stevenson W, Yuen S, Ng AP, Rowley L, Marlton P, Wei AH, Group ALAL. ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL. Blood Advances. 2025;9(6):10.1182/bloodadvances.2024015397
Wei AH, Loo S, Daver N. How I treat patients with AML using azacitidine and venetoclax. Blood. 2025;145(12):10.1182/blood.2024024009
Peng H, Jabbari JS, Tian L, Wang C, You Y, Chua CC, Anstee NS, Amin N, Wei AH, Davidson N, Roberts AW, Huang D, Ritchie ME, Thijssen R. Single-cell Rapid Capture Hybridization sequencing to reliably detect isoform usage and coding mutations in targeted genes. Genome Research. 2025;:10.1101/gr.279322.124
Li K, Yap YQ, Moujalled DM, Sumardy F, Khakham Y, Georgiou A, Jahja M, Lew TE, De Silva M, Luo M-X, Gong J-N, Yuan Z, Birkinshaw RW, Czabotar PE, Lowes K, Huang DCS, Kile BT, Wei AH, Dewson G, van Delft MF, Lessene G. Differential regulation of BAX and BAK apoptotic activity revealed by small molecules. Science Advances. 2025;11(10):10.1126/sciadv.adr8146
Goulart H, Wei AH, Kadia TM. Maintenance Therapy in AML: What Is the Future Potential?. American Journal of Hematology. 2025;100(S2):10.1002/ajh.27583
Chua CC, Loo S, Fong CY, Ting SB, Tiong IS, Fleming SA, Anstee NS, Ivey A, Ashby M, Teh T-C, Reynolds J, Roberts AW, Wei AH. Final Analysis of the Phase 1b Chemotherapy And Venetoclax in Elderly Acute Myeloid Leukaemia Trial (CAVEAT). Blood Advances. 2025;:10.1182/bloodadvances.2024014900
Brown FC, Wang X, Birkinshaw R, Chua CC, Morley T, Kasapgil S, Pomilio G, Blombery P, Huang DCS, Czabotar P, Priore SF, Yang G, Carroll M, Wei AH, Perl AE. Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia. Blood Advances. 2025;9(1):10.1182/bloodadvances.2024014446
